It was released as a blood glucose control treatment for patients with diabetes, but it was approved for use as an obesity treatment by the US Food and Drug Administration (FDA) in 2014, as it was found to be effective for weight loss without hypoglycemia in obese people who did not have diabetes
Other factors worth considering include: Meal timing : As a pragmatic measure (not an evidence-based recommendation), some patients find that avoiding injection immediately before a large meal helps reduce gastrointestinal discomfort, consistent with general advice for incretin-based therapies
Please make 1 injection a day and repeat daily for 3-5 days as required
My skin feels healthier, clearer, and more confident each day
86,87 Differing from the effects observed in T2DM, the therapeutic efficacy of dulaglutide for MASLD is not particularly compelling based on current statistics